PMAM
SABSW icon

Picton Mahoney Asset Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Picton Mahoney Asset Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-125,000
Closed -$115K – 941
2021
Q2 		$115K Sell
125,000
-25,000
-17% -$18.1K ﹤0.01% 648
2021
Q1 		$90K Buy
+150,000
New +$156K ﹤0.01% 312

Other funds holding SABSW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Picton Mahoney Asset Management's SABSW Position: Q3 2021 in Review

Picton Mahoney Asset Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q3 2021, closing a stake of 125,000 shares — an estimated $115K sold.

Picton Mahoney Asset Management first reported a position in SABSW in Q1 2021 and held it in 2 quarters. The position peaked at $115K in Q2 2021. 24 funds tracked by Wall St. Rank hold SABSW as of Q3 2021.

  • Picton Mahoney Asset Management reported no remaining SAB Biotherapeutics Warrant position as of Q3 2021 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 125,000 SAB Biotherapeutics Warrant shares in Q3 2021, an estimated $115K.
  • Picton Mahoney Asset Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 2 quarters.
  • Picton Mahoney Asset Management's SAB Biotherapeutics Warrant position peaked at $115K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q3 2021.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.